Back to top
more

PTC Therapeutics (PTCT)

(Delayed Data from NSDQ)

$32.69 USD

32.69
477,655

-1.16 (-3.43%)

Updated Aug 1, 2024 04:00 PM ET

After-Market: $32.71 +0.02 (0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (98 out of 251)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

PTC Therapeutics (PTCT) Reports Q3 Loss, Tops Revenue Estimates

PTC Therapeutics (PTCT) delivered earnings and revenue surprises of 6.36% and 11.46%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate PTC Therapeutics (PTCT) to Report a Decline in Earnings: What to Look Out for

PTC Therapeutics (PTCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PTC Therapeutics Gets First Milestone Payment for SMA Drug

PTC Therapeutics (PTCT) gets first commercial milestone payment from Roche for first commercial sale of Evrysdi in the United States.

PTC Therapeutics' Application for SMA Drug Accepted by EU

PTC Therapeutics??? (PTCT) MAA for Evrysdi is accepted by the European Medicines Agency for the treatment of spinal muscular atrophy.

PTC Therapeutics (PTCT) Reports Q2 Loss, Lags Revenue Estimates

PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -105.43% and -5.24%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: Should You Buy?

PTC Therapeutics (PTCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PTC Therapeutics to Commence Phase II/III Coronavirus Study in US

PTC Therapeutics (PTCT) gets an FDA sanction to begin a phase II/III study on its DHODH inhibitor PTC299 as a potential treatment of COVID-19. The study will start in the United States shortly.

PTC Therapeutics Initiates Phase II/III Study for Coronavirus

PTC (PTCT) commences a phase II/III study to evaluate PTC299, a dihydroorotate dehydrogenase (DHODH) inhibitor, as a potential treatment for COVID-19.

Pfizer Reports Efficacy & Safety Data on DMD Gene Therapy

Pfizer's (PFE) new phase Ib data on its investigational gene therapy, PF-06939926 in ambulatory boys with DMD support advancement to a pivotal phase III study.

PTC Therapeutics (PTCT) Reports Q1 Loss, Lags Revenue Estimates

PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -55.17% and -13.17%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: PTC Therapeutics (PTCT) Q1 Earnings Expected to Decline

PTC Therapeutics (PTCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Roche's NDA for SMA Drug Gets Expanded Review From FDA

The FDA stretches the review timeline of Roche's (RHHBY) NDA for risdiplam by three months, which is being evaluated to treat spinal muscular atrophy. A decision is now pending on Aug 24, 2020.

PTC Therapeutics (PTCT) Reports Q4 Loss, Tops Revenue Estimates

PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -116.98% and 8.68%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate PTC Therapeutics (PTCT) to Report a Decline in Earnings: What to Look Out for

PTC Therapeutics (PTCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Roche's Risdiplam Meets Primary Endpoint in Infants Study

Roche's (RHHBY) risdiplam meets primary endpoint in FIREFISH study in infants with type 1 spinal muscular atrophy.

Kinjel Shah headshot

4 Drug/Biotech Outperformers That May Lose Steam in 2020

Here we discuss some biotech stocks, which are up this year so far but might not be good additions to your portfolio.

Roche's NDA for SMA Drug Risdiplam Gets Priority Review

The FDA accepts Roche's (RHHBY) NDA for risdiplam under a priority review to treat spinal muscular atrophy. A verdict is pending on May 24, 2020.

Roche's SMA Drug Meets Primary Endpoint in Pivotal Study

Roche's (RHHBY) risdiplam meets primary endpoint in SUNFISH study in SMA patients.

PTC Therapeutics (PTCT) Reports Q3 Loss, Tops Revenue Estimates

PTC Therapeutics (PTCT) delivered earnings and revenue surprises of 2.20% and 5.78%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

PTC Therapeutics (PTCT) Reports Q2 Loss, Tops Revenue Estimates

PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -43.48% and 4.68%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

PTC Therapeutics (PTCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Pfizer's DMD Gene Therapy Shows Severe Side Effects in Study

Pfizer (PFE) presents early data from a study on its investigational gene therapy for DMD. However, the study highlighted some serious side effects in two out of the six participants.

PTC Therapeutics (PTCT) Reports Q1 Loss, Lags Revenue Estimates

PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -22.97% and -24.10%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate PTC Therapeutics (PTCT) to Report a Decline in Earnings: What to Look Out for

PTC Therapeutics (PTCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: PTC Therapeutics (PTCT) Q4 Earnings Expected to Decline

PTC Therapeutics (PTCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.